Mujahed I. Mustafa* and Abdelrafie M. Makhawi
The recent COVID-19 outbreak demonstrated how ineffectively may face newly emerging viruses. Antiviral drugs are the most effective way to combat the COVID-19 pandemic. However, their rapidly declining immunity and a large population of unvaccinated people will provide a recombinant ground for the virus's spread and the era of novel variants, posing a continuous threat of infection for vulnerable groups with inadequate immune responses. In order to treat infected people, effective treatments must be developed. In this short note, discuss a breakthrough in engineered antibody fragment that could be neutralized the shield against the battle of the continuous waves of SARS-CoV-2 variants as well as future other viral infections.
HTML PDFShare this article
Journal of Infectious Diseases and Medicine received 59 citations as per Google Scholar report
